Latest Nicotinic acetylcholine receptor Stories
QUEBEC CITY, Oct. 25, 2011 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that it has been issued U.S. patent No. 8,039,459 from the United States Patent & Trademark Office (USPTO) entitled "Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases." The first patent of this series in the USPTO comprises compounds...
BOSTON, Oct. 20, 2011 /PRNewswire/ -- Additional data will be presented on the mechanistic characterization of adverse events reported with the azole antifungal, voriconazole, and the ketolide antibiotic, telithromycin, at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA). The data will be presented during a poster abstract session at 12:15 to 2:15 p.m. EDT on October 21 in Poster Hall B1. Bertrand et al. had previously shown that inhibition of neuronal nicotinic...
Research could pave the way for development of better drugs to target neurodegenerative diseases For the first time, USC scientists have mapped out a neuroreceptor. This scientific breakthrough promises to revolutionize the engineering of drugs used to treat ailments such as Alzheimer's disease and schizophrenia. The team produced the world's first high-resolution images of the α7 (Alpha 7) receptor, a molecule responsible for transmitting signals between neurons – particularly in...
QUEBEC CITY, Sept. 1, 2011 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that CEO Martin Driscoll will present at the 2011 BioPharm America Conference taking place September 7-9. Mr. Driscoll will provide an overview of Asmacure's nicotinic acetylcholine receptor technology, with emphasis on the company's lead product in...
Researchers at the Faculty of Pharmaceutical Sciences at the University of Copenhagen have collaborated with the company NeuroSearch to generate new knowledge about an important part of the brain's complex communication system. The discovery could form the basis for future development of better medicines for patients with psychiatric disorders. The results were recently published Journal of Neuroscience. New knowledge challenges established scientific ideas about the function of the...
New research in the FASEB Journal suggests that activation of nicotinic receptors within the prefrontal region of the mouse brain helps establish appropriate ranking between competing motivationsIf you think nicotine receptors are only important to smokers trying to kick the tobacco habit, think again. New research published in the FASEB Journal (http://www.fasebj.org) suggests that these receptors also play an important role in social interaction and the ability to choose between competing...
QUEBEC CITY, June 22, 2011 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that CEO Martin Driscoll will be presenting at the 2011 BIO Business Forum during the annual BIO International Convention. Mr. Driscoll's presentation will be given in the Georgetown Room of the Walter E. Washington Convention Center in Washington, DC on...
A team of scientists led by Yale School of Medicine has discovered a brain mechanism that explains how nicotine suppresses appetite "“ findings that could someday help develop medications to help people quit smoking without gaining weight. While previous research shows the average weight gain after quitting smoking is less than 10 pounds, fear of gaining weight can discourage some people from kicking the habit. The current study revealed that a specific subclass of brain nicotinic...
Experts at the Scripps Research Institute campus in Florida have found a genetic mechanism that controls nicotine addiction in the brain--a discovery which could open the door for more effective smoking cessation aids.Lead researcher Paul Kenny, an associate professor with Scripps Research, and colleagues analyzed protein molecules known as nicotinic acetylcholine receptors, or nAChRs. Specifically, they were looking at nAChRs that contained a specific subunit, α5, in order to determine...
Smoking is a common problem for patients with schizophrenia. The increased tendency of patients diagnosed with this disorder is to not only smoke, but to do so more heavily than the general public. This raises the possibility that nicotine may be acting as a treatment for some symptoms of schizophrenia.Nicotine acts through two general classes of brain receptors, those with high and low affinity for nicotine. The low affinity class of nicotinic receptors contains the alpha-7 subunit, which is...
